Drug Expenditure Dynamics 2000–2022

18 Pages

This report provides a detailed analysis of global drug spending trends, adjusting for gaps in public data to better capture total pharmaceutical expenditure, including hospital use and net pricing. It shows that drug spending has remained a relatively stable share of total healthcare expenditure—converging around 15%—despite rising healthcare costs overall. The analysis highlights methodological challenges in cross-country comparisons and offers a more accurate framework for policy discussions.

Join for free to read

Report Drug Expenditure Dynamics 1995–2020

Vendor Sheet IQVIA Rx Dynamics

White Paper Antibody-Drug Conjugates in Cancer Therapy

Case Study Microsoft Dynamics 365 Case Studies

More from IQVIA

Report Drug Expenditure Dynamics 1995–2020

Vendor Sheet IQVIA Rx Dynamics

White Paper Antibody-Drug Conjugates in Cancer Therapy

Vendor Sheet IQVIA Oncology Dynamics: An international survey-based study…

Report

Drug Expenditure Dynamics 2000–2022

Drug Expenditure Dynamics 2000–2022

You Might Also Like

More from IQVIA